NEW YORK (GenomeWeb News) - Nasdaq said Friday that it has dropped Gene Logic from its Biotechnology Index after a semi-annual review of biotechnology companies.
 
According to the Nasdaq website, companies listed on the Biotechnology Index must maintain a market capitalization value of more than $200 million, an average daily trading volume of at least 100,000 shares, and must meet certain other criteria.
 
Gene Logic's market cap is currently listed at $48.6 million with volume of 15,872 shares.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.

Aug
27
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.